Physician profile
Mark A Adams
NPI 1578884581
$2,977.02
in general payments reported to CMS, 2019-2025
23 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.06 · 2020: $34.60 · 2022: $112 · 2023: $785 · 2024: $1,196 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.45 | 2023-2025 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $443.72 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $374.61 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $168.63 | 2020-2025 | |
| Axsome Therapeutics, INC. | $162.54 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $109.27 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $107.59 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $90.87 | 2022-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.12 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $78.81 | 2023-2025 | Trintellix |
| Abbott Laboratories | $76.07 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $70.99 | 2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $60.84 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $48.16 | 2024-2025 | Farxiga, Breztri |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.29 | 2024 | Jardiance |
| Dynavax Technologies Corporation | $34.40 | 2024 | Heplisav-B |
| Exact Sciences Corporation | $33.98 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $31.10 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $23.98 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.37 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $15.17 | 2023 | Rexulti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.